ANIP supply chain intelligence for ANI Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
ANI Pharmaceuticals, Inc. (ANIP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TRUIST-BANK | TRUIST-BANK | 80% | the Company, as borrower, entered into a credit agreement with Truist Bank and other lenders |
| EMMA | Emmaus Life Sciences, Inc. | 72% | Reciprocal relationship from EMMA graph: Reciprocal relationship from ANIP graph: Reciprocal relationship from EMMA graph: these uncertainties. We are dependent on the commercial success of our only … |
| EYPT | EyePoint, Inc. | 72% | Reciprocal relationship from EYPT graph: financial statements. It is important that the discussion of our operating results that follows be read in conjunction with the critical accounting policies d… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HARMONY-BIOSCIENCES | HARMONY-BIOSCIENCES | 92% | Out-licensed intellectual property to Harmony Biosciences in January 2026 |
| CUSTOMER-1 | CUSTOMER-1 | 90% | Customer 1 accounted for 17% of net revenues during the three months ended March 31, 2026 |
| CUSTOMER-2 | CUSTOMER-2 | 90% | Customer 2 accounted for 10% of net revenues during the three months ended March 31, 2026 |
| CUSTOMER-3 | CUSTOMER-3 | 90% | Customer 3 accounted for 16% of net revenues during the three months ended March 31, 2026 |
| CUSTOMER-4 | CUSTOMER-4 | 90% | Customer 4 accounted for 18% of net revenues during the three months ended March 31, 2026 |
| EMMA | Emmaus Life Sciences, Inc. | 72% | Reciprocal relationship from EMMA graph: these uncertainties. We are dependent on the commercial success of our only product, Endari®. Our ability to become profitable will depend upon the commercial… |
| EYPT | EyePoint, Inc. | 72% | Reciprocal relationship from EYPT graph: Reciprocal relationship from ANIP graph: Reciprocal relationship from EYPT graph: financial statements. It is important that the discussion of our operating r… |
| ANIP-ACQUISITION-COMPANY | ANIP-ACQUISITION-COMPANY | 62% | trative Fees and Other Rebates and $ 7.2 million of Prompt Payment Discounts. Administrative Fees and Other Rebates of $ 7.7 million is included in accrued expenses and other in the unaudited condens… |
| HARMONY-BIOSCIENCES-LLC | HARMONY-BIOSCIENCES-LLC | 62% | 78 Other generic revenues 3,818 4,362 Generics and Other total net revenues 109,220 103,040 Total net revenues $ 237,462 $ 197,122 ____________________________________________ (1) There were no sales… |
| NOVITIUM-PHARMA-LLC | NOVITIUM-PHARMA-LLC | 62% | 78 Other generic revenues 3,818 4,362 Generics and Other total net revenues 109,220 103,040 Total net revenues $ 237,462 $ 197,122 ____________________________________________ (1) There were no sales… |
| NURAY-CHEMICALS-PRIVATE-LIMITED | NURAY-CHEMICALS-PRIVATE-LIMITED | 62% | 2026 December 31, 2025 Remaining Weighted Average Amortization Period (1) (in thousands) Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortizat… |
| U-S-BANK-TRUST-COMPANY | U-S-BANK-TRUST-COMPANY | 62% | trative Fees and Other Rebates and $ 7.2 million of Prompt Payment Discounts. Administrative Fees and Other Rebates of $ 7.7 million is included in accrued expenses and other in the unaudited condens… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ANIP-DEBT | Debt stack $301.5M | 90% | Market cache reports total debt of $301.5M. |
| ANIP-DEBT-7763 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ANIP-OWNER-SOLEUS-CAPITAL-MANAGEMENT-L-P | Soleus Capital Management, L.P. | 95% | 13F/ownership overlay lists Soleus Capital Management, L.P.; shares held 820,243; value $63.1B; as of 2026-03-31. |
| ANIP-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD CAPITAL MANAGEMENT LLC; shares held 1,646,128; value $126.6B; as of 2026-03-31. |
| ANIP-OWNER-BLACKROCK-INC | BlackRock, Inc. | 95% | 13F/ownership overlay lists BlackRock, Inc.; shares held 2,747,492; ownership 11.25%; value $211.3B; as of 2026-03-31. |
| ANIP-OWNER-GOLDENTREE-ASSET-MANAGEMENT-LP | GOLDENTREE ASSET MANAGEMENT LP | 95% | 13F/ownership overlay lists GOLDENTREE ASSET MANAGEMENT LP; shares held 667,981; value $51.3B; as of 2026-03-31. |
| ANIP-OWNER-GOLDMAN-SACHS-GROUP-INC | GOLDMAN SACHS GROUP INC | 95% | 13F/ownership overlay lists GOLDMAN SACHS GROUP INC; shares held 620,033; value $48.5B; as of 2026-03-31. |
| ANIP-OWNER-BARCLAYS-PLC | BARCLAYS PLC | 95% | 13F/ownership overlay lists BARCLAYS PLC; shares held 808,708; value $52.0B; as of 2026-03-31. |
| ANIP-OWNER-DEEP-TRACK-CAPITAL-LP | Deep Track Capital, LP | 95% | 13F/ownership overlay lists Deep Track Capital, LP; shares held 600,000; value $46.1B; as of 2026-03-31. |
| ANIP-OWNER-STATE-STREET-CORP | STATE STREET CORP | 95% | 13F/ownership overlay lists STATE STREET CORP; shares held 771,587; value $59.3B; as of 2026-03-31. |
| ANIP-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 95% | 13F/ownership overlay lists MORGAN STANLEY; shares held 733,298; value $60.4B; as of 2026-03-31. |
| ANIP-OWNER-TANG-CAPITAL-MANAGEMENT-LLC | TANG CAPITAL MANAGEMENT LLC | 95% | 13F/ownership overlay lists TANG CAPITAL MANAGEMENT LLC; shares held 707,500; value $54.4B; as of 2026-03-31. |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Mutz Christopher | Head of Rare Disease | sell | 3602 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Stephen P. Carey | SVP & CFO | sell | 4000 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Mutz Christopher | HEAD OF RARE DISEASE | sell | 417 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Walsh Patrick D | CEO | sell | 6000 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Walsh Patrick D | CEO | sell | 6000 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Gassert Chad | SVP - CORP. DEV. & STRATEGY | option_exercise | 11116 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Stephen P. Carey | SVP & CFO | sell | 2773 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Shanmugam Muthusamy | Head of R&D, COO-NOVITIUM OPS | option_exercise | 11116 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Gutwerg Ori | SVP, GENERICS | sell | 2221 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | sell | 500 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Mutz Christopher | Head of Rare Disease | option_exercise | 2221 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | option_exercise | 6021 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Stephen P. Carey | SVP & CFO | sell | 2773 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Gassert Chad | SVP - CORP. DEV. & STRATEGY | option_exercise | 11116 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Gutwerg Ori | SVP, GENERICS | sell | 2221 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Nikhil Lalwani | President & CEO | option_exercise | 12217 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Mutz Christopher | Head of Rare Disease | option_exercise | 2221 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | option_exercise | 6021 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Shanmugam Muthusamy | Head of R&D, COO-NOVITIUM OPS | option_exercise | 11116 shares |
| ANIP | ANI Pharmaceuticals, Inc. | 82% | Nikhil Lalwani | President & CEO | option_exercise | 12217 shares |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| EYPT | EyePoint, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CAH | Cardinal Health, Inc. | 50.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 50.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 50.00 | 2 | |
| MCK | McKesson Corporation | 50.00 | 2 | |
| NVSEF | Novartis AG | 50.00 | 2 | |
| OCUL | Ocular Therapeutix, Inc. | 50.00 | 2 | |
| TELCON | TELCON | 50.00 | 2 | |
| CVS | CVS Health Corporation | 50.00 | 2 |